A novel immunotherapy for relapsed/refractory acute lymphoblastic leukemia (ALL)CANCER RESEARCHIF16.62023-04-040PRE
Raptamer-drug conjugates as molecularly targeted cancer therapeuticsCANCER RESEARCHIF16.62023-04-040PRE
Features that define clinical severity of ulcerative pyoderma gangrenosum: a Delphi consensus study of experts and patients on behalf of the US Medical Dermatology SocietyBRITISH JOURNAL OF DERMATOLOGYIF9.62022-12-195OA
Life and limb protection with dual anti-thrombotic pathway inhibition: COMPASS ushers in a new day in atherothrombotic risk reductionMEDIF11.82021-03-010OAAI
Effect of Patient-Centered Transitional Care Services on Clinical Outcomes in Patients Hospitalized for Heart Failure The PACT-HF Randomized Clinical TrialJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONIF552019-02-26189OAAI
Long-term Follow-up of the Trial of Routine Angioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI)CANADIAN JOURNAL OF CARDIOLOGYIF5.32018-06-0114PREAI
Knowledge to action: Rationale and design of the Patient-Centered Care Transitions in Heart Failure (PACT-HF) stepped wedge cluster randomized trialAMERICAN HEART JOURNALIF3.52018-05-0132PREAI
Efficacy of Early Invasive Management After Fibrinolysis for ST-Segment Elevation Myocardial Infarction in Relation to Initial Troponin StatusCANADIAN JOURNAL OF CARDIOLOGYIF5.32016-10-016PREAI
A Highly Sensitive and Drug-Tolerant Anti-Drug Antibody Screening Assay for Ixekizumab using Affinity Capture ElutionJOURNAL OF INVESTIGATIVE DERMATOLOGYIF5.72016-07-019OAAI
Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid ArthritisJOURNAL OF RHEUMATOLOGYIF3.42015-12-1535PREAI
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsLANCETIF88.52015-08-01723PREAI
A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumabJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGYIF82015-03-1322OAAI
Improvement of scalp and nail lesions with ixekizumab in a phase 2 trial in patients with chronic plaque psoriasisJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGYIF82015-02-1863PREAI
IL-17 Induces Inflammation-Associated Gene Products in Blood Monocytes, and Treatment with Ixekizumab Reduces Their Expression in Psoriasis Patient BloodJOURNAL OF INVESTIGATIVE DERMATOLOGYIF5.72014-12-0148OAAI
Efficacy of an Early Invasive Strategy After Fibrinolysis in ST-Elevation Myocardial Infarction Relative to the Extent of Coronary Artery DiseaseCANADIAN JOURNAL OF CARDIOLOGYIF5.32014-12-016PREAI
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasisJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGYIF11.82014-12-0190PREAI
Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome ReflectiveCANADIAN JOURNAL OF CARDIOLOGYIF5.32014-12-0123PREAI
Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasisJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGYIF82014-10-30110PREAI
Efficacy and safety of a routine early invasive strategy after fibrinolysis stratified by glycoprotein IIb/IIIa inhibitor use during percutaneous coronary intervention: a pre-specified subgroup analysis of the TRANSFER-AMI randomised controlled trialHEARTIF4.42014-01-212PREAI
Clinical outcomes and cost implications of routine early PCI after fibrinolysis: One-year follow-up of the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) studyAMERICAN HEART JOURNALIF3.52013-04-0121PREAI